Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab monotherapy in active rheumatoid arthritis
NCT02121210Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of sarilumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Incidence of Antidrug Antibodies at Week 30. Started Jun 2014; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02121210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121210.